Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584610 | 0.79 | TAAR1 (0.39) | KMT2ATAAR1ALDH1A1AR | |
| SCHEMBL28651733 | 0.79 | TAAR1 (0.43) | LMNAKMT2ATAAR1PTPN1IDO1 | |
| SCHEMBL3026103 | 0.78 | IDO1 (0.41) | LMNATAAR1IDO1DAOALDH1A1 | |
| SCHEMBL3306954 | 0.78 | HTR2A (0.56) | LMNAKMT2ATAAR1PTPN1IDO1 | |
| SCHEMBL2585956 | 0.77 | CALM1 (0.43) | KDM4E | |
| SCHEMBL711973 | 0.76 | CALM1 (0.57) | LMNAIDO1KDM4EALDH1A1 | |
| SCHEMBL7459476 | 0.76 | ALOX5 (0.43) | KMT2APTPN1HTR2A | |
| SCHEMBL9561120 | 0.76 | HTR2A (0.41) | LMNAKMT2APTPN1HTR2AKDM4E | |
| SCHEMBL27425612 | 0.75 | LTA4H (0.40) | TAAR1 | |
| SCHEMBL8914827 | 0.74 | IDO1 (0.43) | KMT2ATAAR1IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | claimed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | claimed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | claimed |
| CN-102639495-A | Pyrrolidine GPR40 Modulators | BRISTOL MYERS SQUIBB CO | 2012-08-15 | — | — | CN | claimed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | claimed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | claimed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | claimed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | claimed |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | JOHN VARGHESE | 2007-06-28 | — | — | US | claimed |
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | claimed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135581-A1 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | LMNA 1333/4885KMT2A 782/4885TAAR1 1940/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | LMNA 1166/4885KMT2A 596/4885TAAR1 1466/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | LMNA 1333/4885KMT2A 782/4885TAAR1 1940/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | LMNA 501/4885KMT2A 3534/4885TAAR1 2256/4885 |
| US-20070149584-A9 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ASPH, DNPEP, APP | LMNA 1333/4885KMT2A 782/4885TAAR1 1940/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | LMNA 1166/4885KMT2A 596/4885TAAR1 1466/4885 |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | LMNA 1427/4885KMT2A 854/4885TAAR1 1798/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | LMNA 1166/4885KMT2A 596/4885TAAR1 1466/4885 |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | LMNA 4812/4885KMT2A 3563/4885TAAR1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.